41,911 Shares in DexCom, Inc. (NASDAQ:DXCM) Purchased by WINTON GROUP Ltd

WINTON GROUP Ltd acquired a new stake in DexCom, Inc. (NASDAQ:DXCM) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 41,911 shares of the medical device company’s stock, valued at approximately $3,259,000.

Other institutional investors have also modified their holdings of the company. Versant Capital Management Inc purchased a new stake in shares of DexCom in the fourth quarter valued at approximately $25,000. Private Trust Co. NA grew its stake in DexCom by 266.3% in the 4th quarter. Private Trust Co. NA now owns 337 shares of the medical device company’s stock valued at $26,000 after acquiring an additional 245 shares during the period. TD Private Client Wealth LLC increased its holdings in DexCom by 62.8% in the 4th quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company’s stock worth $34,000 after acquiring an additional 167 shares in the last quarter. Larson Financial Group LLC raised its position in DexCom by 40.5% during the fourth quarter. Larson Financial Group LLC now owns 475 shares of the medical device company’s stock worth $37,000 after acquiring an additional 137 shares during the period. Finally, Heck Capital Advisors LLC purchased a new position in DexCom during the fourth quarter valued at $38,000. Hedge funds and other institutional investors own 97.75% of the company’s stock.

DexCom Stock Performance

Shares of DexCom stock opened at $69.47 on Friday. The business’s fifty day simple moving average is $82.65 and its 200-day simple moving average is $77.02. The company has a quick ratio of 1.28, a current ratio of 1.47 and a debt-to-equity ratio of 0.59. The firm has a market cap of $27.15 billion, a PE ratio of 48.58, a price-to-earnings-growth ratio of 2.30 and a beta of 1.28. DexCom, Inc. has a 52 week low of $62.34 and a 52 week high of $141.99.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. Equities analysts forecast that DexCom, Inc. will post 2.03 earnings per share for the current year.

Insider Activity at DexCom

In related news, CEO Kevin R. Sayer sold 32,498 shares of the firm’s stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total transaction of $2,287,209.24. Following the completion of the transaction, the chief executive officer now directly owns 372,029 shares in the company, valued at $26,183,401.02. This trade represents a 8.03 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, COO Jacob Steven Leach sold 2,634 shares of the business’s stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $228,920.94. Following the sale, the chief operating officer now owns 268,644 shares in the company, valued at $23,347,850.04. This trade represents a 0.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 105,009 shares of company stock worth $8,044,178. Insiders own 0.30% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on DXCM. Morgan Stanley boosted their target price on shares of DexCom from $75.00 to $82.00 and gave the stock an “equal weight” rating in a research note on Friday, February 14th. Canaccord Genuity Group boosted their price objective on DexCom from $99.00 to $103.00 and gave the stock a “buy” rating in a research note on Friday, February 14th. Robert W. Baird upgraded DexCom from a “neutral” rating to an “outperform” rating and raised their target price for the company from $86.00 to $104.00 in a research report on Thursday, January 16th. Wells Fargo & Company reiterated an “overweight” rating on shares of DexCom in a research report on Saturday, March 8th. Finally, Baird R W upgraded DexCom from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 16th. Five investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $99.82.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.